One of the most common targets of the antitumor effect of Apigenin is the mTOR/PI3K axis [9,114], which is frequently inhibited by micromolar concentrations of Apigenin in a dose-dependent manner in several cancer cell lines, including bladder, breast, colon, lymphoma, liver, leukemia, prostate, and melanoma [9,98,102,127,128,129]. The gene discussed is MTOR; the disease is cancer.